FH deficiency also protects cancer cells from drugs targeting mitochondrial ETC and causing a metabolic catastrophe, as demonstrated in FH-deficient UOK262 cells treated with ONC201 [59], an anti-GBM agent that decreases OXPHOS-mediated production of ATP [60]. This evidence concerns the gene FH and glioblastoma.